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Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Hepatitis B virus X protein
(HBx) contributes to the development of HCC, whereas HBx with COOH-terminal deletion is a frequent event in the
HCC tissues. Previously, we identified a natural mutant of HBx-truncated 27 amino acids at the COOH-terminal
(termed HBxΔ127), which strongly enhanced cell growth. In the present study, we focused on investigating the
mechanism. Accordingly, fatty acid synthase (FAS) plays a crucial role in cancer cell survival and proliferation; thus,
we examined the signaling pathways involving FAS. Our data showed that HBxΔ127 strongly increased the transcrip-
tional activities of FAS in human hepatoma HepG2 and H7402 cells. Moreover, we found that 5-lipoxygenase (5-LOX)
was responsible for the up-regulation of FAS by using MK886 (an inhibitor of 5-LOX) and 5-LOX small interfering RNA.
We observed that HBxΔ127 could upregulate 5-LOX through phosphorylated extracellular signal–regulated protein
kinases 1/2 and thus resulted in the increase of released leukotriene B4 (LTB4, a metabolite of 5-LOX) by ELISA. The
additional LTB4 could upregulate the expression of FAS in the cells as well. Interestingly, we found that FAS was able
to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Collectively,
HBxΔ127 promotes cell growth through a positive feedback loop involving 5-LOX and FAS, in which released LTB4 is
involved in the up-regulation of FAS. Thus, our finding provides a new insight into the mechanism involving the pro-
motion of cell growth mediated by HBxΔ127.
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Introduction
Hepatitis B virus (HBV) infection is a major global health problem,
and more than 350 million people in the world are infected by HBV
[1]. The small 3.2-kb DNA genome of HBV has four partially over-
lapping open reading frames: preC/C, P, preS/S, and X gene. Hepatitis B
virus X protein (HBx) is an important regulator that regulates many
kinds of host processes by interaction with the virus and host factors
[2]. HBx can disrupt normal expression of proteins involved in tran-
scriptional regulation, cell cycle control, protein degradation pathways,
apoptosis, genetic stability metabolism, immune response, and cell ad-
hesion [3]. However, studies have demonstrated that mutations and
deletions of HBx, especially the COOH-terminal deletion of HBx,
are frequently events in the HBV-associated hepatocellular carci-
noma tissues [4–6]. HBxΔ127 is a natural mutant of the HBx gene
with deletion from 382 to 401 bp [7], which is similar to the report
of Liu et al. [4]. Our data demonstrated that HBxΔ127 was able to
upregulate transcriptional activities of nuclear factor κB, survivin, and
human telomerase reverse transcriptase, as well as the expression levels
of c-Myc and proliferating cell nuclear antigen in the hepatoma cells
[7]. In addition, it has been reported that mutations of the HBx gene
might produce uncontrolled growth and contribute tomultistep hepato-
carcinogenesis [8]. Therefore, the mutations of HBx gene are very
important in hepatocarcinogenesis [4,9–12]. However, the mechanism
of HBx mutant in hepatocarcinogenesis remains unclear. Hence, it is
necessary to demonstrate its molecular mechanism.
HBx plays critical roles in the induction of various liver failures in-
cluding up-regulation of lipid synthesis–related genes and dysregulation
of hepatic metabolism [13]. However, the mechanism that HBx accu-
mulates fatty acid is largely unknown because no proper system is avail-
able to study the pathogenesis. Fatty acid synthase (FAS) is an important
enzyme involved in de novo lipid synthesis and triglyceride accumulation
in hepatocytes by catalyzing the reaction of acetyl-CoA and malonyl-
CoA into palmitate that is esterified into triglyceride [14]. Although
constitutively expressed at a very low or undetectable level, the trans-
cription of FAS gene is highly upregulated in various human malig-
nancies [15]. Inhibition of FAS showed strong antitumor effects,
including cell cycle arrest and apoptosis in various human cancer cells,
such as breast, prostate, colon, and ovarian cell lines [16–19]. Treatment
of human breast and prostate cancer xenografts in athymic mice with
FAS inhibitors has shown a significant antitumor effect without tox-
icity to proliferating normal tissues such as bone marrow, skin, liver,
and gastrointestinal tract [18,19]. Importantly, the treatment of tumor
cells with pharmacologic inhibitors of FAS leads to cell cycle arrest
followed by apoptosis of the tumor cells [20–22]. Therefore, the highly
expressed FAS is considered as a molecular marker in cancer cells [23].
Several studies suggested that FAS expression is primarily regulated at
the transcriptional level by sterol regulatory element binding protein 1
(SREBP-1) [24]. Shimano et al. [25] found that SREBPs mediated
FAS transcriptional regulation in the liver and adipose tissue by over-
expressing the constitutively active mature forms of SREBP-1. Another
study also showed that the HBx protein could induce the up-regulation
of SREBP-1 and FAS by interacting with LXRα and could enhance
the binding of LXRα to the LXR response element [26]. Thus, we
suppose that HBxΔ127 may regulate cell proliferation through fatty
acid metabolisms.
Recent studies demonstrated that arachidonic acid metabolites are
associated with cancer development. Three key enzymes, including
cyclooxygenase (COX), lipoxygenase (LOX), and epoxygenase (cyto-
chrome P450, CYP4), can metabolize arachidonic acid to biologically
active eicosanoids, such as leukotrienes (LTs), hydroperoxyeicosatet-
raenoic acids, hydroxy-eicosatetraenoic acid, and prostaglandins, which
play an important role in cancer cell proliferation [27,28]. For instance,
5-lipoxygenase (5-LOX) converts arachidonic acid to hydroxyeicosate-
traenoic acids or LTs, which are able to enhance proliferation, increase
survival, and suppress the apoptosis of human cells. Our laboratory
previously found that COX-2, 5-LOX, and phosphorylated extracellu-
lar signal–regulated protein kinases 1/2 (p-ERK1/2) were involved in
the proliferation and migration of breast cancer LM-MCF-7 cells with
high metastatic potential [29]. Therefore, we hypothesize that the
promotion of cell growth mediated by HBxΔ127 maybe involved in
arachidonic acid metabolism as well as FAS.
In the present study, we investigated the underlying mechanism
involving the promotion of cell growth mediated by HBxΔ127.
Our finding showed that HBxΔ127 could upregulate the expression
of 5-LOX through p-ERK1/2. The released LTB4, a metabolite of
5-LOX, was able to upregulate the expression of FAS. Thus, we con-
clude that HBxΔ127 promotes cell growth through a positive feed-
back loop involving 5-LOX and FAS.
Materials and Methods
Cell Culture
Human hepatoma HepG2 and H7402 cells were maintained in
Dulbecco’s modified Eagle medium (Gibco, Santa Clara, CA) supple-
mented with heat-inactivated 10% fetal calf serum, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin in a humidified atmosphere of 5%
CO2 and 95% air at 37°C.
Reagents, Plasmids, and Transfection
MK886, indomethacin (Indo), PD98059 (an inhibitor of mitogen-
activated protein kinase kinase), and LTB4 were purchased from Sigma-
Aldrich (St. Louis, MO). Cerulenin was purchased from Fermentek Ltd
(Jerusalem, Israel). The enzyme immunoassay kit for measuring LTB4
was purchased from Adlitteram Diagnostic Laboratories (San Diego,
CA). The plasmids of pCMV-X, pCMV-XΔ127, and pSilencer3.0-X
were described previously [7,30]. The plasmids of pFAS-WT-Luc,
pFAS-ΔSRE-Luc, SREBP-1c-571-Luc-WT, and pcDNA3-DN-
SREBP-1 were obtained from Dr. Q. Liu (University of Saskatchewan,
Canada) [31]. The small interfering RNA (siRNA) targeting messenger
RNA (mRNA) of 5-LOX and the negative control siRNAwere designed
and synthesized by RiboBio (Guangzhou, China). The engineered cells
of HepG2-X/H7402-X (stably transfected with the pCMV-X plasmid),
HepG2-XΔ127/H7402-XΔ127 (stably transfected with the pCMV-
XΔ127 plasmid), and HepG2-pCMV/H7402-pCMV (stably trans-
fected with the empty pCMV-Tag2B vector plasmid) were generated in
hepatomaHepG2 andH7402 cells, respectively, using the Lipofectamine
method according to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA). The successful stable transfection ofHBx andHBxΔ127 genes were
confirmed by reverse transcription–polymerase chain reaction (RT-PCR)
and Western blot analyses.
Nitro Blue Tertrazolium Assay
To examine the cytotoxicity mediated by the tested inhibitors, the
HepG2 and the HepG2-XΔ127 (or H7402 and H7402-XΔ127) cells
were cultured in a 96-well plate for 24 hours as previously mentioned;
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after that, the cells were recultured in serum-free medium for 12 hours.
In brief, HepG2 and HepG2-XΔ127 (or H7402 and H7402-XΔ127)
cells were treated withMK886 (5, 10, or 20 μM) for 6 hours, with Indo
(10, 20, or 50 μM) for 6 hours, and with cerulenin (2.5, 5, or 10 μg/ml)
for 12 hours, respectively. The cell cytotoxicity was analyzed by the
reduction of nitro blue tertrazolium (NBT, Sigma-Aldrich). Briefly,
0.75 μM NBTwas added into the previously mentioned treated cells,
which were then incubated at 37°C for 1 hour. Then, the cells were ob-
served under a lightmicroscope to examine at an absorbance of 560 nm.
The conditions of the NBTassay were adapted from Wei et al. [32].
Treatments of Tumor Cells
HepG2 and HepG2-XΔ127 cells (or H7402 and H7402-XΔ127
cells) were cultured in serum-free medium for 12 hours. Briefly, the
engineered cells were treated withMK886 (5, 10, or 20μM) for 6 hours
and with Indo (10, 20, or 50 μM) for 6 hours, respectively. The engi-
neered cells were treated with PD98059 (20, 35, or 50 μM) for 4 hours.
In a separate experiment, the supernatants derived from the HepG2-
XΔ127 (or H7402-XΔ127) cell cultures, termed HepG2-XΔ127 CM
(or H7402-XΔ127 CM) and the boiled supernatants HepG2-XΔ127
BCM (or H7402-XΔ127 BCM), were harvested and stored at −80°C
until use as a conditioned medium for cell treatment. HepG2-XΔ127
(or H7402-XΔ127) cells were pretreated by the inhibitors, such as
MK886 or Indo, for 6 hours and were subsequently recultured in fresh
medium for 48 hours after three washes with the fresh medium; the
supernatants were harvested and stored at −80°C until use as a condi-
tioned medium. HepG2 (or H7402) cells were cultured for 48 hours,
followed by treatment with 50% or 100% HepG2-XΔ127 CM (or
H7402-XΔ127 CM) and HepG2-XΔ127 BCM (or H7402-XΔ127
BCM) for 24 hours, as controls HepG2 (or H7402) cells were also
treated with 100% HepG2-XΔ127 CM (or H7402-XΔ127 CM),
which were pretreated with 20 μM MK886 for 6 hours. In this study,
HepG2 (orH7402) cells were treatedwith LTB4 (0.1, 1, 10, or 100 nM)
for 3, 6, and 12 hours. HepG2 (or H7402) cells were treated with
100 nM LTB4, followed by the treatment with MK886 (5, 10, or
20 μM) for 6 hours. HepG2 and HepG2-XΔ127 (or H7402 and
H7402-XΔ127) cells were treated with cerulenin (2.5, 5, or 10 μg/ml)
for 12 hours. The treated cells were subjected to luciferase reporter
gene assays, real-time PCR, immunoblot analysis, and enzyme-linked
immunosorbent assay (ELISA), respectively.
Luciferase Reporter Gene Assays
The treated cells were harvested after 48 hours and lysed in 1×
passive lysis buffer. The luciferase activity was determined by using Dual-
Luciferase Reporter Assay System (Promega, Madison, WI) on a Lumino-
meter (TD-20/20; Turner Designs, Sunnyvale, CA) according to the
manufacturer’s instructions. The pCMV-Tag2B empty vector, pGL3-basic
plasmid, andmockwere used as controls. Luciferase activity was normalized
for transfection efficiency using the corresponding Renilla luciferase activity.
All experiments were performed at least three times. The data of luciferase
reporter gene assays were analyzed by Student’s t test for statistical differ-
ences. P < .05 was considered statistically significant.
RNA Extraction and Real-time PCR
Extraction of total RNA of the cells and reverse transcription were car-
ried out as described previously [33]. Real-time PCR was performed
using the SYBR Premix Ex Taq II PCR kit (Takara, China). One micro-
liter of eachRTreactionwas PCR-amplified in a 25-μl aliquot containing
2.5 mM MgCl2, 0.4 μM gene-specific primers, and 1× SYBR Green
Master Mix. Amplification was performed on an iQ5 Real-time PCR
System (Bio-Rad,Hercules, CA) according to themanufacturer’s instruc-
tions. The relative amounts of mRNA were calculated using the ΔΔC t
method [34] with β-actin as the endogenous reference gene amplified
from the samples. The sequences of the primers are given in Table W1.
RNA Interference Experiment
HepG2-XΔ127 (or H7402-XΔ127) cells were transfected with a
pSilencer-X vector that produces siRNA that targets the HBxΔ127
mRNA or control siRNA [30]. Duplex siRNA targeting bases 315 to
335 (5′-GCGCAAGTACTGGCTGAATGA-3′) of the human 5-LOX
mRNA (NM_000698) were introduced into HepG2-XΔ127 (or
H7402-XΔ127) cells according to the manufacturer’s protocol. Each
experiment included controls containing the transfection reagent with
control siRNA. Luciferase reporter gene assays and real-time PCR were
performed 48 hours after the transfection.
Western Blot Analysis
The treated cells were washed three times with ice-cold PBS and ex-
tracted directly in the lysis buffer (62.5mMTris-HCl, pH6.8, 2%SDS,
5% 2-mercaptoethanol, 10% glycerol), respectively. The equal amounts
of protein (30 μg) were separated by 12% SDS–polyacrylamide gel
electrophoresis and transferred onto a poly vinilidene difluoride mem-
branes for 90 minutes. The membrane was blocked in blocking buffer
(PBS, 5% skimmilk, 0.1% Tween 20) at room temperature for 2 hours
and then incubated with the appropriate primary antibody (diluted
in blocking buffer). The primary antibodies included anti-Flag and
anti-actin (Sigma-Aldrich), anti-HBx (Abcam, Cambridge, UK), anti–
5-LOX (Santa Cruz Biotechnology, Santa Cruz, CA), and anti–
p-ERK1/2 (Cell Signaling Technology, Danvers, MA). The membranes
were washed thee times in PBS (0.1% Tween 20) and incubated for
1 hour with the secondary antibody (peroxidase-conjugated antirabbit
or antimouse immunoglobulin G). The membranes were then washed
thee times, and the bands were visualized by an enhanced chemilumi-
nescence reagent (Amersham Pharmacia Biotech, Piscataway, NJ).
Enzyme-Linked Immunosorbent Assay
The amount of LTB4 (a metabolite of 5-LOX) was determined by
ELISA according to the manufacturer’s instructions. The concentration
of LTB4 was normalized to the total protein. The protein concentra-
tions in these extracts were determined using a standard protein assay
method (Bio-Rad Laboratories, Inc, Hercules, CA).
Flow Cytometry Analysis
The detailed procedures of flow cytometry analysis were performed
accordingly [7]. Briefly, HepG2-XΔ127 (or H7402-XΔ127) cells were
grown in serum-free Dulbecco’s modified Eagle medium for 12 hours
and then treated with 10 μg/ml cerulenin for 12 hours and 20 μM
MK886 for 6 hours, respectively. At the end of incubation, cells were
harvested and washed twice in PBS and resuspended in 200 μl of PBS
followed by the addition of 2 ml of 70% ice-cold ethanol and fixed
overnight at 4°C. Then, 100 μl of RNaseA (1 mg/ml) and 100 μl of
propidium iodide (100 mg/ml) were added into the cell suspensions
and incubated at 37°C for 30 minutes, followed by examination of
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cell proliferation by FACScan flow cytometer (Becton Dickinson, San
Jose, CA). Cell proliferative index (PI) is the sum of the S and G2/M
phase activities of the cell cycle expressed as a fraction of the total cell
population, i.e., PI = [(S + G2 / M) / (G0 / G1 + S + G2 / M)] × 100 [7].
Data are representative of three independent experiments.
Statistical Analysis
Statistical analyses were performed using SigmaPlot 2001 (Systat Soft-
ware, Inc, Richmond,CA; http://www.systat.com). Statistical significance
was assessed by comparing the mean values (±SD) using a Student’s t test
or χ 2 test.
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Results
HBxΔ127 Upregulates Expression of FAS
Our previous study showed that HBxΔ127 could significantly pro-
mote the proliferation of hepatoma cells [7]. Here, we try to identify the
molecular mechanism. Recently, it has been reported that FAS is asso-
ciated with the progression of many kinds of tumor and that FAS is
primarily regulated at the transcriptional level. To investigate whether
FAS is involved in promoting cell proliferation mediated by HBxΔ127,
we examined the effect of HBxΔ127 on the transcription of FAS. First,
we established the engineered cell lines including HepG2-X (or
H7402-X) and HepG2-XΔ127 (or H7402-XΔ127). The expressions
of HBx and HBxΔ127 at the mRNA and protein levels in the engi-
neered cells were determined by RT-PCR (Figure 1A) andWestern blot
analysis (Figure 1B), respectively.
Then, we investigated whether HBxΔ127 could influence the
transcriptional activity of FAS using pFAS-WT-Luc, a FAS promoter-
luciferase reporter. The finding showed that HBxΔ127 could signifi-
cantly increase the transcriptional activity of FAS relative to the controls
(P < .01, Student’s t test; Figure 1, C and D). Meanwhile, RNA inter-
ference (RNAi) targeting HBx mRNA was able to abolish the up-
regulation of FAS (P < .001, Student’s t test; Figure 1E). In addition,
we found that HBxΔ127 was able to upregulate FAS at the mRNA level
in HepG2-XΔ127 (or H7402-XΔ127) cells (P < .001, Student’s t test;
Figure 1F ). The down-regulation of HBxΔ127 mediated by RNAi
targeting HBx mRNA could abolish the up-regulation of FAS at the
mRNA level (P < .001, Student’s t test; Figure 1, G and H ).
HBxΔ127 Upregulates Transcriptional Activity of FAS
through SREBP-1
Because SREBP-1 is a major transcriptional factor for the transcrip-
tional regulation of FAS by binding to the SRE site, we examined the
transcriptional activity of FAS by using FAS-ΔSRE–Luc, a truncated
FAS promoter-luciferase reporter without the SREBP binding site
(ΔSRE). Our data showed that the luciferase activity of FAS was barely
detected by pFAS-ΔSRE–Luc promoter reporter (Figure 1, C and D).
Furthermore, to verify the involvement of SREBP-1 in HBxΔ127-
induced FAS up-regulation, the DN–SREBP-1, a plasmid encoding a
dominant-negative (DN) mutant SREBP-1 protein was transfected
into HepG2-XΔ127 (or H7402-XΔ127) stable cells, together with
the wild-type FAS promoter reporter. The results revealed that the
luciferase activity of FAS was significantly decreased in DN-SREBP-
1–transfected cells while having no effect in control vector–transfected
Figure 1. HBxΔ127 upregulates the expression of FAS in hepatoma HepG2 (or H7402) cells. (A) HBx and HBxΔ127 genes were identified
in HepG2-X and HepG2-XΔ127 (or H7402-X and H7402-XΔ127) cells by RT-PCR. (B) The expression of HBx and HBxΔ127 was detected
by immunoblot analysis. (C) Luciferase reporter gene assay showed that the transcriptional activities of FAS were higher in HepG2 cells
when cotransfecting the plasmids of pFAS-WT-Luc and pCMV-X or pCMV-XΔ127 than controls by transient transfection, suggesting that
HBxΔ127 has stronger ability to upregulate FAS than HBx. However, pCMV-X or pCMV-XΔ127 failed to stimulate pFAS-ΔSRE-Luc (a mutant
of FAS promoter) as control. The data are representative of three independent experiments. Values represent mean ± SD (n= 3). *P< .05,
**P< .01, ***P< .001 (Student’s t test). (D) The previously mentioned experiments were repeatable in another hepatoma H7402 cells. (E) In
stable transfection system, pSilencer-X plasmid (RNAi targeting mRNA ofHBxΔ127) could abolish the enhancement of transcriptional activ-
ities of FAS in HepG2-XΔ127 (or H7402-XΔ127) cells by luciferase reporter gene assay in a dose-dependent manner. The data are represen-
tative of three independent experiments. Values represent mean ± SD (n = 3). *P < .05, **P < .01, ***P < .001 (Student’s t test). (F) The
expression levels of FAS mRNA in HepG2-XΔ127 (or H7402-XΔ127) cells were examined by real-time PCR. Plotted are the means ± SD of
three samples normalized to β -actin. Statistically significant differences relative to FASmRNA levels in HepG2 (or H7402) cells, arbitrarily set
to 1.0, are indicated: *P< .05, **P< .01, ***P< .001 (Student’s t test). (G, H) The expression levels of FASmRNA inHepG2-XΔ127 (or H7402-
XΔ127) cells transfected with a pSilencer-X plasmid were examined by real-time PCR. Plotted are the means ± SD of three samples normal-
ized to β -actin. Statistically significant differences relative to FAS mRNA levels in HepG2-XΔ127 (or H7402-XΔ127) cells, arbitrarily set to 1.0,
are indicated: *P < .05, **P < .01, ***P < .001 (Student’s t test).
Figure 2. HBxΔ127 upregulates FAS promoter activity through SREBP-1. (A) The transcriptional activity of FAS was examined by luciferase
reporter gene assay in HepG2-XΔ127 cells when cotransfectionwas performed using plasmids of pCDNA3.1 (empty vector) or DN–SREBP-1
(a mutant of SREBP-1). The data showed that DN–SREBP-1 was able to inhibit the transcriptional activity of FAS by competition with wild
type SREBP-1 in HepG2-XΔ127 cells, suggesting that HBxΔ127 upregulates FAS promoter activity through SREBP-1. Data are representative
of three independent experiments. Values represent mean ± SD (n = 3). ***P < .001 (Student’s t test). (B) The previously mentioned ex-
periments were repeatable in H7402-XΔ127 cells. Data are representative of three independent experiments. Values represent mean ± SD
(n = 3). ***P < .001 (Student’s t test).
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cells (P < .001, Student’s t test; Figure 2, A and B). Thus, these data sug-
gest that the up-regulation of FASmediated byHBxΔ127 is involved in
the SREBP-1–FAS pathway.
5-LOX Is Responsible for the Up-regulation of FAS
Arachidonic acid is an important intermediate in lipid metabolism,
whose catalyzing enzymes, COX-2 and 5-LOX, are overexpressed
during multistage tumor progression in many neoplastic disorders in-
cluding lung, breast, and pancreatic cancers and hepatocellular carci-
noma integrated HBx gene in host hepatocytes [35,36]. Therefore, we
suppose that the arachidonic acid metabolism may be correlated with
the up-regulation of FAS mediated by HBxΔ127. First, we examined
the cytotoxicity of MK886 (a specific 5-LOX inhibitor), Indo (a
COX-2 inhibitor), and cerulenin (a FAS inhibitor) in HepG2 and
HepG2-XΔ127 (or H7402 and H7402-XΔ127) cells, respectively, by
NBT assay. The data showed that the dose of inhibitors used in this
experiment has no cytotoxicity to HepG2 and HepG2-XΔ127 (or
H7402 and H7402-XΔ127) cells (Figure W1). In addition, we also
detected the effect of these inhibitors on the expression of HBxΔ127
in HepG2-XΔ127 (or H7402-XΔ127) cells by immunoblot analysis.
The result showed that MK886, Indo, and cerulenin could not affect
the expression of HBxΔ127 (Figure W2), respectively. Furthermore,
we treated the engineered cells with MK886 and Indo for 6 hours.
We found that MK886 could abolish the up-regulation of FAS in
HepG2-XΔ127 (or H7402-XΔ127) cells in a dose-dependent manner
by luciferase reporter gene assays (P < .05, vs control, Student’s t test;
Figure 3, A and B) and real-time PCR (P < .05, vs control, Student’s
t test; Figure 3C ). However, treatment with Indo failed to affect the
expression level of FAS (Figure 3, A–C ). In addition, we found that
siRNA targeting of the mRNA of 5-LOX could significantly attenuate
the mRNA levels of FAS in HepG2-XΔ127 (or H7402-XΔ127) as well
(P < .05, vs control, Student’s t test; Figure 3, D and E ), which is
consistent with the previously mentioned observation. As controls, we
treatedHepG2 (orH7402) cells withMK886 and Indo for 6 hours. The
results showed that MK886 was able to decrease the intrinsic FAS in
HepG2 (or H7402) cells rather than Indo (Figures W3 and
W4). Thus, our finding suggests that 5-LOX is responsible for the
up-regulation of FAS mediated by HBxΔ127.
HBxΔ127 Upregulates the Expression of 5-LOX
through p-ERK1/2
Accordingly, HBxΔ127 upregulates the expression of FAS, mean-
while 5-LOX is responsible for the up-regulation of FAS mediated by
HBxΔ127, so we examined whether HBxΔ127 upregulated the expres-
sion of 5-LOX. Our data showed that, relative to controls, the expres-
sion level of 5-LOX was upregulated at the mRNA and protein levels in
HepG2-XΔ127 (or H7402-XΔ127) cells by real-time PCR (P < .05, vs
control, Student’s t test; Figure 4A) and immunoblot analysis, respec-
tively (Figure 4B). Interestingly, RNAi targeting mRNA of HBxΔ127
could abolish the up-regulation of 5-LOX (Figure 4, A and B), suggest-
ing that HBxΔ127 is responsible for the up-regulation of 5-LOX. The
up-regulation of 5-LOX should increase the amount of the metabolites
of 5-LOX, so we determined the amount of LTB4, a metabolite of
5-LOX, in both of the conditioned media of HepG2/HepG2-XΔ127
(or H7402/H7402-XΔ127) cells and the cell lysates by ELISA. We
found that the amount of LTB4 was higher in the conditioned
medium of HepG2-XΔ127 (or H7402-XΔ127) cells relative to the
conditioned medium of HepG2 (or H7402 cells), which could be
abolished by RNAi targeting mRNA of HBxΔ127 (P < .05, Student’s
t test; Figure 4C ). Our previous work found that p-ERK1/2 could
upregulate cPLA2, COX-2, 5-LOX, and 12R-LOX expression in
LM-MCF-7 cells or MDA-MB-231 cells [29]. Therefore, we supposed
that p-ERK1/2 may be involved in the up-regulation of 5-LOX in
HepG2-XΔ127 (or H7402-XΔ127) cells. Then, we examined the
effect of p-ERK1/2 on the expression level of 5-LOX in HepG2-
XΔ127 (or H7402-XΔ127) cells. We found that the treatment with
50 μM PD98059 (a specific inhibitor of mitogen-activated protein
kinase kinase) could abolish the up-regulation of 5-LOX in HepG2-
XΔ127 (or H7402-XΔ127) cells at the mRNA and protein levels by
real-time PCR and Western blot analysis (Figure 4D). Thus, we con-
clude that HBxΔ127 is able to upregulate the expression of 5-LOX
through p-ERK1/2.
LTB4 Activates the Expression of FAS
Accordingly, we identified whether LTB4 was involved in the up-
regulation of FAS. We examined the effect of conditioned medium
from HepG2-XΔ127 (or H7402-XΔ127) cells on the expression of
FAS in HepG2 (or H7402) cells. Luciferase reporter gene assay showed
that the treatment with conditioned medium (boiled or not) from
HepG2-XΔ127 (or H7402-XΔ127) cells led to a strong up-regulation
of FAS in HepG2 (or H7402) cells in a dose-dependent manner.
However, when HepG2 (or H7402) cells were treated with 100%
HepG2-XΔ127 CM (or H7402-XΔ127 CM), which were pretreated
with 20 μM MK886 for 6 hours, the up-regulation of FAS was abol-
ished (P < .05, Student’s t test; Figure 5A), suggesting that the released
Figure 3. 5-LOX is responsible for the up-regulation of FASmediated by HBxΔ127. (A) The transcriptional activities of FASwere examined by
luciferase reporter gene assay in HepG2-XΔ127 cells when the MK886 (an inhibitor of 5-LOX) and Indo (an inhibitor of COX-2) were used,
respectively. Data are representative of three independent experiments. Values represent mean± SD (n=3). *P< .05 versus control, **P<
.01 versus control, ***P< .001 versus control (Student’s t test). (B) The experiments were repeated in HepG2-XΔ127 (or H7402-XΔ127) cells
in a dose-dependent and time course manner. Data are representative of three independent experiments. Values represent mean± SD (n=
3). *P< .05 versus control, **P< .01 versus control, ***P< .001 versus control (Student’s t test). (C) HepG2-XΔ127 (or H7402-XΔ127) cells
(2 × 105) were incubated with or without MK886 (5, 10, and 20 μM) for 6 hours. The mRNA levels of FAS were examined by real-time PCR.
Plotted are the means ± SD of three samples normalized to β -actin. Statistically significant differences relative to FAS mRNA levels in
HepG2-XΔ127 (or H7402-XΔ127) cells, arbitrarily set to 1.0, are indicated: *P < .05, **P < .01, ***P < .001 (Student’s t test). (D) HepG2-
XΔ127 cells were transfected with 100 nM 5-LOX siRNA or control siRNA for 48 hours. Then, the transcriptional activities of FAS were
examined by luciferase reporter gene assay. Data are representative of three independent experiments. Values represent mean ± SD
(n = 3). **P < .01 versus control (Student’s t test). (E) Real-time PCR showed the expression levels of FAS mRNA in control cells and
5-LOX siRNA-transfected HepG2-XΔ127 (or H7402-XΔ127) cells. Plotted are the means ± SD of three samples normalized to β -actin. Sta-
tistically significant differences relative to FASmRNA levels in HepG2-XΔ127 (or H7402-XΔ127) cells, arbitrarily set to 1.0, are indicated: *P<
.05, **P < .01, ***P < .001 (Student’s t test).
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Figure 4. HBxΔ127 upregulates the expression levels of 5-LOX and increases the release of LTB4 (ametabolite of 5-LOX). (A) The expression
level of 5-LOXwas increased inHepG2-XΔ127 (or H7402-XΔ127) cells by real-timePCR,whichwas abolished byRNAi targetingmRNAofHBx
gene using pSilencer3.0-X plasmid. Plotted are the means ± SD of three samples normalized to β -actin. Statistically significant differences
relative to control, arbitrarily set to 1.0, are indicated: *P< .05, **P< .01, ***P< .001 (Student’s t test). (B) The expression level of 5-LOXwas
examined by Western blot analysis as well. (C) The level of LTB4 was determined by ELISA in the conditioned medium or in the cell lysates
from HepG2-X/HepG2-XΔ127 (or H7402-X/H7402-XΔ127) cells. The amount of LTB4 in HepG2/HepG2-pCMV (or H7402/H7402-pCMV) cells
was used as control. Data are representative of three independent experiments. Values represent mean ± SD (n= 3). * P< .05, ** P< .01,
***P< .001 (Student’s t test). (D) HepG2-XΔ127 (or H7402-XΔ127) cellswere treatedwith orwithout PD98059 (20, 35, and 50μM) for 4 hours.
Then, we examined the mRNA levels of 5-LOX by real-time PCR. Plotted are the means ± SD of three samples normalized to β -actin. Statis-
tically significant differences relative to FAS mRNA levels in HepG2-XΔ127 (or H7402-XΔ127) cells, arbitrarily set to 1.0, are indicated: *P <
.05, **P < .01, ***P < .001 (Student’s t test). The protein expression levels of 5-LOX were examined by Western blot analysis. The protein
levels of HBxΔ127 and p-ERK1/2 were also determined as controls.
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metabolites in the conditioned medium of HepG2-XΔ127 (or H7402-
XΔ127) cells contribute to the up-regulation of FAS.
On cell activation, 5-LOX is translocated to the perinuclear mem-
brane where it converts arachidonic acid into many metabolites, for
example, bioactive lipid intermediate LTB4 [37]. To further confirm
the role of LTB4 in the up-regulation of FAS, we pretreated HepG2
(or H7402) cells with exogenous LTB4. The data showed that exoge-
nous LTB4 could upregulate the expression level of FAS in HepG2 (or
H7402) cells in a dose-dependent manner by luciferase reporter gene
assays (P < .01, Student’s t test; Figure 5B) and real-time PCR (P <
.05, Student’s t test; Figure 5D), respectively. Notably, the exogeneous
LTB4-mediated up-regulation of FAS could be completely abolished by
pretreatment with 20μMMK886by luciferase reporter gene assays (P <
.05, Student’s t test; Figure 5C) and real-time PCR (P < .05, Student’s
t test; Figure 5E ), suggesting that LTB4 is responsible for the up-
regulation of FAS.
FAS Upregulates the Expression Level of 5-LOX in a Positive
Feedback Manner
To further examine the signal transduction pathways involving 5-
LOX and FAS, we suppose that FAS could activate 5-LOX in a positive
feedback manner mediated by HBxΔ127 in HepG2-XΔ127 (or
H7402-XΔ127) cells. Interestingly, the treatment with 10 μg/ml ceru-
lenin, an inhibitor of FAS, could greatly downregulate the expression of
5-LOX at the mRNA and protein levels in HepG2-XΔ127 (or H7402-
XΔ127) cells (P < .05, Student’s t test; Figure 6, A and B). As controls,
we treated HepG2 (or H7402) cells with 10 μg/ml cerulenin. The re-
sults revealed that the cerulenin could decrease the intrinsic 5-LOX in
HepG2 (or H7402) cells (Figures W5 and W6). In addition, we exam-
ined the effect of cerulenin on LTB4 by ELISA.We found that 10μg/ml
cerulenin could largely decrease the amount of released LTB4 in the
conditioned medium of HepG2-XΔ127 (or H7402-XΔ127) cells and
cell lysates in a dose-dependent manner (P < .05, Student’s t test;
Figure 6C), suggesting that HBxΔ127 promotes and keeps the prolifer-
ation through a positive feedback loop involving FAS and 5-LOX.
HBxΔ127 Enhances Cell Growth through FAS and 5-LOX
Furthermore, we investigated the effect of FAS and 5-LOX on the pro-
liferation in the HepG2-XΔ127 (or H7402-XΔ127) cells by flow cyto-
metry analysis. The results showed that 10 μg/ml cerulenin and 20 μM
MK886 could significantly decrease the cell proliferation of HepG2-
XΔ127 (or H7402-XΔ127) cells according to the percentage of cells in
Sphase and PI (P < .05 vs control, Student’s t test; FigureW7), suggesting
that HBxΔ127 enhanced cell proliferation by FAS and 5-LOX.
Discussion
FAS is a key enzyme capable of the reductive de novo synthesis of long-
chain fatty acids from acetyl-CoA, malonyl-CoA, and nicotinamide
adenine dinucleotide phosphate [38]. Its expression and activity are
extremely low in nearly all nonmalignant adult tissues, whereas it is
highly expressed in most human cancers as well as in precancerous le-
sions with a poor prognosis [39–43], with levels increasing as tumor
grade and severity increase [39,40]. The up-regulation of FAS is asso-
ciated with poor prognosis. Therefore, the enzyme has been recognized
in recent years as a target of antitumor therapy [41]. Jensen et al.
showed that the high expression of FAS together with a high PI of
breast cancer cells (>17%) were associated with a nine-fold increased
risk of patient mortality [42,44].
Increasing studies have suggested that the X gene contains a frequent
deletion in COOH-terminal region [4–6]. In addition, it has been
showed that the COOH-terminal–truncated HBx rather than the
full-length HBx could effectively transform immortalized liver cell line
MIHA in vitro and in vivo, and the expression profiling revealed dif-
erential expression of key genes that were involved in the control of
cell cycle and apoptosis [12], which strongly suggest that the COOH-
terminal–truncated HBx plays a key role in hepatocarcinogenesis
through activating cell proliferation. In our present study, we used a
C-terminal deletion of hepatitis B virusX protein (HBxΔ127) [7],which
is similar to the report of Liu et al. [4], to demonstrate the molecular
mechanism as a model. Interestingly, we found that HBxΔ127 upregu-
lated the expression of FAS at the levels of transcriptional activity and
mRNA, in which the effect of HBxΔ127 on up-regulating FAS
was stronger relative to the wild-type HBx (Figure 1). Then, we demon-
strated that the up-regulation of FASwas involved in the FAS–SREBP-1
pathway (Figure 2), which is consistent with the finding [26]. However,
the mechanism is unclear. So we try to identify the activators involving
the up-regulation of FAS mediated by HBxΔ127. It has been reported
that arachidonic acid or its metabolites are able to stimulate tumor cell
proliferation. Several studies have confirmed that the metabolites of 5-
LOX were able to enhance cell proliferation and increase cell survival
[12]. The expression of 5-LOX is increased in different human cancers,
such as breast and prostate cancers [45]. Arachidonic acid can be con-
verted to 5-hydroperoxyeicosatetraenoic acid by 5-LOX, and then to
LTA4, all of which show certain levels of biologic activity in humans
[46,47]. However, LTA4 can be further hydrolased to LTB4 by LTA4
hydrolase [48,49]. Several studies have demonstrated that LTB4 can en-
hance cell proliferation and suppress apoptosis in human cancer cells and
that it is an important chemoattractant in the fields of immunology and
hematology [46,48]. A recent study found that the expression levels of
FAS, COX-2, and 5-LOX played important roles in mediating breast
cancer formation [50]. Therefore, we present a hypothesis that arachido-
nic acid metabolism and FAS expression may contribute to sustaining a
high proliferation rate mediated by the HBxΔ127.
Interestingly, we found that HBxΔ127 upregulated the expression of
FAS in HepG2-XΔ127 (or H7402-XΔ127) cells through 5-LOX by
using MK886 (a specific inhibitor of 5-LOX) rather than Indo (an in-
hibitor of COX-2) (Figure 3). Moreover, we confirmed that HBxΔ127
could increase the expression of 5-LOX through p-ERK1/2 in HepG2-
XΔ127 (or H7402-XΔ127) cells (Figure 4). We also examined the
Figure 4. (continued).
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amount of LTB4 (a metabolite of 5-LOX) by ELISA. The data showed
that the amount of LTB4 was significantly increased in both of the
conditioned medium of HepG2-XΔ127 (or H7402-XΔ127) cells
and cell lysates relative to the controls (Figure 4C ). So we used the con-
ditioned medium of HepG2-XΔ127 (or H7402-XΔ127) cells to treat
the HepG2 (or H7402) cells. The data showed that the conditioned
media were able to upregulate the expression of FAS (Figure 5A), sug-
gesting that the high level of LTB4 released in the conditioned medium
was responsible for the up-regulation of FAS. To further confirm the role
of LTB4 in the up-regulation of FAS, we used 100 nMexogenesis LTB4
to treat HepG2 (or H7402) cells. The results further demonstrated that
LTB4 could upregulate the expression of FAS in HepG2 (or H7402)
Figure 5. LTB4 is involved in the up-regulation of FAS. (A) HepG2 (or H7402) cells were transfected with 0.3 μg of plasmid of FAS
promoter-luciferase reporter gene, respectively. We treated the transfected cells with conditioned medium (CM) from HepG2-XΔ127
(or H7402-XΔ127) cells or boiled conditioned medium (BCM) from HepG2-XΔ127 (or H7402-XΔ127) cells at indicated the different con-
centration for 12 hours before the cell lysates were obtained and luciferase activity was measured. In addition, HepG2 (or H7402) cells
were also treated with 100% HepG2-XΔ127 CM (or H7402-XΔ127 CM), which were pretreated with 20 μMMK886 for 6 hours. Data are
representative of three independent experiments. Values represent mean ± SD (n = 3). *P < .05 versus control, **P < .01 versus
control, ***P < .001 versus control (Student’s t test). (B) HepG2 (or H7402) cells were transfected with 0.3 μg of plasmid of FAS
promoter-luciferase reporter gene, respectively. We treated the transfected cells with the addition of 0.1, 1, 10, or 100 nM LTB4 or
without LTB4 at different time points (3, 6, and 12 hours) before cell lysates were obtained and luciferase activity was measured. Data
are representative of three independent experiments. P < .01 (Student’s t test) (C) HepG2 (or H7402) cells were incubated with the
addition of 100 nM LTB4 together with 5, 10, or 20 μM MK886 for 6 hours before cell lysates were obtained and luciferase activity
was measured. Data are representative of three independent experiments. Values represent mean ± SD (n= 3). *P< .05 versus control,
**P < .01 versus control, ***P < .001 versus control (Student’s t test). (D) HepG2 (or H7402) cells were treated with the addition of LTB4
(0.1, 1, 10, or 100 nM) for 12 hours. Then, the FAS mRNA was examined by real-time PCR, respectively. Plotted are the means ± SD of
three samples normalized to β -actin. Statistically significant differences relative to FAS mRNA levels in HepG2 (or H7402) cells, arbitrarily
set to 1.0, are indicated: *P< .05, **P< .01, ***P< .001 (Student’s t test). (E) HepG2 (or H7402) cells were incubated with the addition of
100 nM LTB4 together with 5, 10, or 20 μM MK886 for 6 hours. The mRNA levels of FAS were examined by real-time PCR, respectively.
Plotted are themeans± SDof three samples normalized to β -actin. Statistically significant differences relative to FASmRNA levels in HepG2
(or H7402) cells without MK886, arbitrarily set to 1.0, are indicated: *P < .05, **P < .01, ***P < .001 (Student’s t test).
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Figure 6. FAS contributes to the up-regulation of 5-LOX in a positive feedback loop manner. HepG2-XΔ127 (or H7402-XΔ127) cells (2 × 105)
were incubated with or without cerulenin (2.5, 5, and 10 μg/ml) for 12 hours. (A) The mRNA level of 5-LOX was detected by real-time PCR.
Plotted are the means ± SD of three samples normalized to β -actin. Statistically significant differences relative to 5-LOX mRNA levels in
HepG2-XΔ127 (or H7402-XΔ127) cells without the action of cerulenin, arbitrarily set to 1.0, are indicated: *P < .05, **P < .01, ***P < .001
(Student’s t test). (B) The protein expression level of 5-LOXwas examined byWestern blot analysis. (C, D) The amount of LTB4was examined
by ELISA in the conditionedmedium or in the cell lysates from the previously mentioned treated HepG2-XΔ127 (or H7402-XΔ127) cells. Data
are representative of three independent experiments. Values representmean± SD (n=3). *P< .05 versus control, **P< .01 versus control,
***P < .001 versus control (Student’s t test).
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cells (Figure 5B), which could be abolished by the pretreatment of
MK886 (Figure 5C ). Thus, we conclude that HBxΔ127 enhances
the expression of FAS through 5-LOX and released LTB4.
Previously, we reported that breast cancer cells grow faster in a posi-
tive feedback manner involving activated ERK and COX/LOX [29].
In this study, we suppose that HBxΔ127 may promote cell growth
in a similar way, such as a positive feedback loop involving FAS and
5-LOX. Therefore, we used 10 μg/ml cerulenin (an inhibitor of FAS)
to treat HepG2-XΔ127 (or H7402-XΔ127) cells. Interestingly, we
found that the inactivation of FAS could downregulate the expression
level of 5-LOX in HepG2-XΔ127 (or H7402-XΔ127) cells and de-
crease the amount of LTB4 (a metabolite of 5-LOX) in both of the con-
ditioned media of HepG2-XΔ127 (or H7402-XΔ127) cells and cell
lysates (Figure 6), suggesting that HBxΔ127 promotes cell growth
through a positive feedback loop involving FAS and 5-LOX in hepa-
toma cells.
Taken together, our data reveal a novel signal transduction pathway
involving a positive feedback loop between FAS and 5-LOX,which con-
tributes to cell growth mediated by HBxΔ127. This finding provides a
new insight into a mechanism of promotion of cell growth mediated by
HBx mutants.
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Table W1. List of Primers Used in this Paper.
Number Position Product (bp) Forward (5′ to 3′) Reverse (5′ to 3′)
HBx AB104894 +1 to +465 465 ATGGCTGCTAGGGTGTGCTG CTAGGCAGAGGTGAAAAAGTTGC
HBxΔ127 AB104894 +1 to +381 381 ATGGCTGCTAGGGTGTGCTG AATCTCCTCCCCCAACTCCTCCC
pCMV-tag2B AF072539 +620 to +844 224 AATTAACCCTCACTAAAGGG TAATACGACTCACTATAGGG
FAS NM_004104 +6036 to +6232 196 GGTCTTGAGAGATGGCTTGC AATTGGCAAAGCCGTAGTTG
5-LOX NM_000698 +1469 to +1884 415 CCCGGGGCATGGAGAGCA GCGGTCGGGCAGCGTGTC
β-Actin NM_001101 +687 to +995 308 AGCGGGAAATCGTGCGTG CAGGGTACATGGTGGTGCC
Figure W1. Examination of cytotoxicity mediated by MK886 (an in-
hibitor of 5-LOX), Indo (an inhibitor of COX-2), and cerulenin (an inhib-
itor of FAS) by NBT assay.We treated the cells withMK886 (5, 10, or
20 μM) for 6 hours, Indo (10, 20, or 50 μM) for 6 hours, and cerulenin
(2.5, 5, or 10 μg/ml) for 12 hours, respectively. The NBT assay show-
ing that the dose of inhibitors used in this experiment has no cyto-
toxicity to HepG2, HepG2-XΔ127, H7402, and H7402-XΔ127 cells.
Figure W2. Effect of MK886, Indo, and cerulenin on the expression
ofHBxΔ127.HepG2-XΔ127 (orH7402-XΔ127) cells (2×105) plated in
six-well plateswere pretreatedwith 20μMMK886 for 6 hours, 50μM
Indo for 6 hours, and 10 μg/ml cerulenin for 12 hours, respectively.
The expression level of HBxΔ127 was not influenced by the dose of
inhibitors used by Western blot analysis.
Figure W3.MK886 decreased the transcriptional activities of FAS in
HepG2 cells. As control, we detected the effect of MK886 or Indo on
the transcriptional activities of FAS in HepG2 cells by luciferase re-
porter gene assay. The data showed that 20 μMMK886 was able to
inhibit the transcriptional activities of FAS rather than Indo. Data are
representative of three independent experiments. Values represent
mean± SD (n=3). *P< .05 versus control, **P< .01 versus control
(Student’s t test).
Figure W4. MK886 inhibited the mRNA level of FAS in HepG2 (or
H7402) cells. HepG2 (or H7402) cells (2 × 105) plated in six-well
plateswere pretreatedwith 20 μMMK886 or 50 μM Indo for 6 hours,
respectively. At the end of incubation, the mRNA expression level of
FASwas examined by RT-PCR, respectively. The results showed that
the 20 μMMK886 was able to inhibit the intrinsic mRNA level of FAS
rather than Indo.
Figure W6. Cerulenin (a FAS inhibitor) decreased theexpression level
of 5-LOX in HepG2 (or H7402) cells. HepG2 (or H7402) cells (2 × 105)
plated in six-well plates were incubated with 10 μg/ml cerulenin for
12 hours. Western blot analysis showing that the intrinsic expression
Figure W7. Proliferation index: S phase fraction analysis by FACS: (a) HepG2-XΔ127, (b) HepG2-XΔ127 cells treatedwith 10 μg/ml cerulenin,
(c) HepG2-XΔ127 cells treated with 20 μMMK886, (d) H7402-XΔ127, (e) H7402-XΔ127 cells treated with 10 μg/ml cerulenin, and (f) H7402-
XΔ127 cells treatedwith 20μMMK886.Data are representative of three independent experiments. Values representmean±SD (n=3). *P<
.05 versus control, **P < .01 versus control, ***P < .001 versus control (Student’s t test).
Figure W5. Cerulenin (a FAS inhibitor) decreased the intrinsicmRNA
level of 5-LOX in HepG2 (or H7402) cells. HepG2 (or H7402) cells (2×
105) plated in six-well plateswere pretreatedwith 10 μg/ml cerulenin
for 12 hours. At the end of incubation, the mRNA expression level of
5-LOX was examined by RT-PCR. The results showed that the intrin-
sicmRNA level of 5-LOXwas downregulated by10μg/ml cerulenin in
HepG2 (or H7402) cells.
